drugset / Trial / NCT02568345
Sugammadex ED90 Dose in the Obese Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the minimum effective dose of sugammadex, an antagonist of neuromuscular blockade used during anesthesia practice, in obese patients, considering that sugammadex is indicated in adults with normal weight at a dose of 2 mg/kg but no studies were found with obese patients.
Timeline
- Start
- 2013-01
- Primary completion
- 2013-10
- Completion
- 2014-01
Publications
- Background 1983 metropolitan height and weight tables. Stat Bull Metrop Life Found. 1983 Jan-Jun;64(1):3-9. No abstract available.
- Background Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet. 1984 Mar-Apr;9(2):177-83. doi: 10.2165/00003088-198409020-00005.
- Background Blouin RA, Kolpek JH, Mann HJ. Influence of obesity on drug disposition. Clin Pharm. 1987 Sep;6(9):706-14.
- Background de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007 Aug;107(2):239-44. doi: 10.1097/01.anes.0000270722.95764.37.
- Background Donati F. Sugammadex: a cyclodextrin to reverse neuromuscular blockade in anaesthesia. Expert Opin Pharmacother. 2008 Jun;9(8):1375-86. doi: 10.1517/14656566.9.8.1375.
- Background Duffull SB, Dooley MJ, Green B, Poole SG, Kirkpatrick CM. A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet. 2004;43(15):1167-78. doi: 10.2165/00003088-200443150-00007.
- Background Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003 Sep;99(3):632-7; discussion 6A. doi: 10.1097/00000542-200309000-00018.
- Background Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051-65. doi: 10.2165/00003088-200544100-00004.
- Background Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987 Oct 22;317(17):1098. doi: 10.1056/NEJM198710223171717. No abstract available.
- Background Nicholson WT, Sprung J, Jankowski CJ. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy. 2007 Aug;27(8):1181-8. doi: 10.1592/phco.27.8.1181.
- Background Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother. 2000 Sep;34(9):1066-9. doi: 10.1345/aph.19381.
- Background Renes SH, van Geffen GJ, Rettig HC, Gielen MJ, Scheffer GJ. Minimum effective volume of local anesthetic for shoulder analgesia by ultrasound-guided block at root C7 with assessment of pulmonary function. Reg Anesth Pain Med. 2010 Nov-Dec;35(6):529-34. doi: 10.1097/AAP.0b013e3181fa1190.
- Background Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006 Apr;104(4):667-74. doi: 10.1097/00000542-200604000-00009.
- Background Stylianou M, Flournoy N. Dose finding using the biased coin up-and-down design and isotonic regression. Biometrics. 2002 Mar;58(1):171-7. doi: 10.1111/j.0006-341x.2002.00171.x.
- Results Demirkaya M, Kelsaka E, Sarihasan B, Bek Y, Ustun E. The optimal dose of remifentanil for acceptable intubating conditions during propofol induction without neuromuscular blockade. J Clin Anesth. 2012 Aug;24(5):392-7. doi: 10.1016/j.jclinane.2011.11.006.
- Results Garrett-Mayer E. The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. 2006;3(1):57-71. doi: 10.1191/1740774506cn134oa.
- Results George RB, McKeen D, Chaplin AC, McLeod L. Up-down determination of the ED(90) of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing Cesarean delivery. Can J Anaesth. 2010 Jun;57(6):578-82. doi: 10.1007/s12630-010-9297-1. Epub 2010 Mar 18.
- Results Gupta PK, Hopkins PM. Effect of concentration of local anaesthetic solution on the ED(5)(0) of bupivacaine for supraclavicular brachial plexus block. Br J Anaesth. 2013 Aug;111(2):293-6. doi: 10.1093/bja/aet033. Epub 2013 Mar 26.
- Results Hammer GB, Litalien C, Wellis V, Drover DR. Determination of the median effective concentration (EC50) of propofol during oesophagogastroduodenoscopy in children. Paediatr Anaesth. 2001;11(5):549-53. doi: 10.1046/j.1460-9592.2001.00731.x.
- Results Hennebry MC, Stocks GM, Belavadi P, Barnes J, Wray S, Columb MO, Lyons G. Effect of i.v. phenylephrine or ephedrine on the ED50 of intrathecal bupivacaine with fentanyl for caesarean section. Br J Anaesth. 2009 Jun;102(6):806-11. doi: 10.1093/bja/aep095. Epub 2009 May 2.
- Results Kodaka M, Suzuki T, Maeyama A, Koyama K, Miyao H. Gender differences between predicted and measured propofol C(P50) for loss of consciousness. J Clin Anesth. 2006 Nov;18(7):486-9. doi: 10.1016/j.jclinane.2006.08.004.
- Results Llaurado S, Sabate A, Ferreres E, Camprubi I, Cabrera A. Sugammadex ideal body weight dose adjusted by level of neuromuscular blockade in laparoscopic bariatric surgery. Anesthesiology. 2012 Jul;117(1):93-8. doi: 10.1097/ALN.0b013e3182580409.
- Results Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a precis of clinical use, study design, and dose estimation in anesthesia research. Anesthesiology. 2007 Jul;107(1):144-52. doi: 10.1097/01.anes.0000267514.42592.2a.
- Results Stylianou M, Proschan M, Flournoy N. Estimating the probability of toxicity at the target dose following an up-and-down design. Stat Med. 2003 Feb 28;22(4):535-43. doi: 10.1002/sim.1351.
- Results Taha AM, Abd-Elmaksoud AM. Lidocaine use in ultrasound-guided femoral nerve block: what is the minimum effective anaesthetic concentration (MEAC90)? Br J Anaesth. 2013 Jun;110(6):1040-4. doi: 10.1093/bja/aes595. Epub 2013 Feb 5.
- Results Van Lancker P, Dillemans B, Bogaert T, Mulier JP, De Kock M, Haspeslagh M. Ideal versus corrected body weight for dosage of sugammadex in morbidly obese patients. Anaesthesia. 2011 Aug;66(8):721-5. doi: 10.1111/j.1365-2044.2011.06782.x. Epub 2011 Jun 21.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sugammadex | Other / unclassified | 2 mg/kg | — |
| Subject | Sugammadex | Other / unclassified | 2.2 mg/kg | — |
| Subject | Sugammadex | Other / unclassified | 2.4 mg/kg | — |
| Subject | Sugammadex | Other / unclassified | 2.6 mg/kg | — |
| Subject | Sugammadex | Other / unclassified | 2.8 mg/kg | — |
Indications
No indication recorded.